To thwart drug counterfeiting, the SFDA has tightened up some regulations on contract manufacturing organizations, notably on rules governing cross-border interactions. Most significantly, the SFDA will no longer allow third-parties to operate between a CMO and the pharma that holds the marketing authorization for a product. The contact between the CMO and a foreign pharma must be direct. More details....

Share this with colleagues: